年度归档 2025年3月28日

　　This year, Fujian Province Tendering and Purchasing Group Co., Ltd. witnessed great events and good deeds.

　　Brand, won the annual top ten brands of China tendering agency, the top 100 consulting service agencies of China PPP project, and the national advanced productivity model enterprise award; In the main business, the provincial environmental protection design institute, the design institute of the University of Technology and the consulting supervision of the University of Technology have become a member of the group in different forms, such as capital increase and holding, decoupling and transfer, and are moving towards a comprehensive technical service group; Strategically, high-tech industrialization projects such as large-capacity solid-state lithium batteries, intelligent robots and three-dimensional codes, which have invested or participated in, are progressing smoothly, making a good start for a new round of transformation and development; In terms of capital operation, Fujian Tendering Co., Ltd. was formally established, and the "6 18" industrial equity investment fund entered operation …

　　In the structural reform of the supply side, the provincial bidding group has formed a trend of "double highs" of high-end service industry and high-tech industry. "In the face of the new normal of economic development, with the guidance and support of the provincial SASAC, we focus on developing three major sectors of business. While providing excellent engineering and technical consulting services, we integrate resources to invest in new formats such as modern logistics parks, and rely on the’ 6 18′ platform to develop high-tech industries." Chen Wu, Party Secretary and Chairman of the Group, summed up the development ideas of the Group.

　　Seize the opportunity to create new advantages in the main business

　　In mid-October this year, 20 departments, including the Ministry of Finance and the Ministry of Education, jointly announced the third batch of government-social capital cooperation (PPP) demonstration projects, and 25 projects in Fujian Province were listed, 15 of which were consulted by Fujian Provincial Bidding and Purchasing Group. It is no accident that this achievement was achieved.

　　Fujian tendering and purchasing group was formerly known as Fuzhou mechanical and electrical equipment tendering company, which was established in 1988. In 1990, it became the institution directly under the former Provincial Economic and Trade Commission. In 1992, it was renamed as Fujian mechanical and electrical equipment tendering company. In 2010, it was restructured with the approval of the provincial government and became the only technical service group enterprise among provincial state-owned enterprises.

　　Over the years, the Provincial Tendering and Purchasing Group has kept up with the new development direction of the industry, constantly improved the industrial chain of engineering technical consulting services, and formed business sectors such as engineering consulting, tendering agency, cost consulting, project agent construction, engineering supervision, engineering design, test and geographical mapping, etc. It has obvious advantages in technical consulting services such as bidding, and its business scale and economic benefits have always been among the best in the technical consulting industry of engineering construction projects in China.

　　"The 18th National Congress of the Communist Party of China proposed that the market should play a decisive role in resource allocation, and the PPP model has become an important measure for the reform of investment and financing systems in various places. We promptly deployed excellent teams and set up PPP consulting centers, becoming the first batch of warehousing PPP consulting institutions in Fujian Province, providing project owners with consulting services in the whole process, such as preliminary preparation, investment selection and social capital, negotiation and assistance in signing agreements. " Chen Wu said.

　　The Provincial Tendering Group has also developed and built an electronic tendering and purchasing platform in combination with "internet plus" to help the work of the national electronic tendering and bidding innovation pilot province in our province. The platform for purchasing bulk materials, the exhibition platform for state-owned enterprises and private enterprises, and the 6.18 "Double Creation" cloud platform are being gradually popularized and applied with the support of relevant departments. With the help of "internet plus", the Group has continuously broadened the breadth and depth of services, vigorously developed high-end services throughout the process, and changed to professional and consulting services, effectively upgrading the main business of existing technical consulting services.

　　Break through the new format of orderly layout in change

　　On December 2nd, at the "2016′ Sky Map Fujian’ Achievement Application Promotion Conference" hosted by the Provincial Basic Geographic Information Center, Fujian Jingwei Surveying and Mapping Information Co., Ltd. proposed a complete solution based on the UAV’s’ Sky Map Fujian’ small area image rapid update mechanism, which aroused great interest of the docking party.

　　In the information age, data is king. Jingwei Surveying and Mapping Company, an enterprise owned by Provincial Tendering Group, got rid of the shackles of traditional surveying and mapping, made great efforts to tap the socialized application of surveying and mapping geographic information industry, further expanded the application of surveying and mapping geographic information in smart cities, smart transportation, smart tourism and other industries, and actively created consumer goods based on surveying and mapping information, such as food, clothing, housing and transportation, which served the public, and achieved fruitful results.

　　In recent years, in the process of integration and reorganization, the provincial bidding group has repeatedly made moves to integrate resources from all sides, create new advantages and lay out new formats.

　　With the transfer of Provincial Traffic Construction Engineering Supervision Consulting Co., Ltd., Provincial Road Port Engineering Consulting Co., Ltd. and Provincial Traffic Construction Engineering Test and Detection Co., Ltd. into wholly-owned subsidiaries, the Group has increased investment in high-end equipment and consolidated the authority and leading advantages of these companies in traffic engineering related fields in our province. In September last year, Provincial Traffic Construction Engineering Test and Testing Co., Ltd. passed the national laboratory accreditation qualification evaluation. In June this year, the provincial and local standard "Technical Specification for Inspection and Evaluation of Prestressed Construction Quality of Highway Engineering Concrete Bridges" edited by the company passed the examination and approval of the Provincial Bureau of Quality and Technical Supervision, filling the gap in our province; In November, two provincial and local standards, "Technical Specification for Testing Compactness of Road Fill Subgrade by Electromagnetic Method" and "Technical Specification for Installation and Replacement of Bridge Bearings", were reviewed and approved.

　　While laying a solid foundation, the Group is building an experimental testing base in Pushang Industrial Zone, Jinshan, Fuzhou, which provides good conditions for the development of testing business to be specialized, sophisticated and sophisticated. While investing in the establishment of Fujian Intelligent Maintenance Engineering Co., Ltd., it will integrate the superior resources of all ownership enterprises and apply big data to develop businesses focusing on health inspection and intelligent maintenance of roads and bridges.

　　The provincial tendering group also cooperated with Putian Jiaotou Group to develop the logistics park project of Putian train freight station area. While providing comprehensive project development consultation and construction management, Fujian Minzhao Logistics Park Construction and Development Co., Ltd. will be jointly funded to carry out unified planning, investment, financing, construction and management of park projects, and introduce social capital investment or organize logistics enterprises to participate in investment and development. This project, with a total investment of 5.8 billion yuan, plans to build five parks, namely, e-commerce logistics zone, multimodal transport logistics zone, smart logistics industrial zone, commerce logistics zone and bulk cargo logistics zone, which will be built into a demonstration industrial park in Putian City, integrating e-commerce and its supporting facilities, interacting with the sales, distribution, warehousing and trade of products in surrounding industrial parks, forming a seamless connection with physical stores, and creating a new format of modern logistics construction and operation.

　　In addition, this year, it also signed a strategic cooperation framework agreement with Ningde Urban Construction Group, which will carry out all-round cooperation in project management, engineering consulting services and investment and development of new logistics platforms.

　　Keep a close eye on "6 18" and cultivate new growth points

　　Recently, Fujian Judian New Energy Co., Ltd., a holding subsidiary of the bidding group, completed the bidding for the renovation project of the comprehensive office building, and is preparing to start related projects. The company introduced the patented technology of "Large-capacity solid-state power lithium battery" from Beijing Shenzhou Judian, implemented industrialization in Wuyi New District, and will produce large-capacity polymer lithium-ion batteries by stages.

　　Marching into high-tech industries, the provincial bidding group is taking solid steps.

　　In 2015, the provincial government decided to hand over the market-oriented operation function of the China Strait Project Fair (referred to as "6 18"), which has been successfully held for more than ten sessions, and approved the group to initiate the establishment of the "6 18" industrial equity investment fund to carry out the incubation and industrialization of the "6 18" docking project.

　　Seize the opportunity of docking cutting-edge scientific and technological achievements, the provincial tendering group has successively invested and established Fujian 618 Industrial Development Co., Ltd., Minzhao Industrial Investment Fund Management Co., Ltd., 618 Information Technology Co., Ltd. and other ownership companies.

　　This year, "6 18" was operated by the group for the first time. According to the work arrangement of the provincial party committee and government, closely centering on the "June 18th" strategic plan, and under the guidance of the provincial development and reform commission, the provincial tendering group promoted all the work with the concept of "government guidance, market-oriented operation and professional management" and achieved good results.

　　The Group also organized professional teams to actively search for high-tech projects in line with the national and provincial key industrial policies through the "6 18" platform. On the one hand, the "6.18" industrial equity investment fund will drive more social capital to participate in the incubation and industrialization of the "6.18" docking project and strengthen the transformation effect of the "6.18" project; On the other hand, it directly participates in the landing industrialization of some projects by means of equity investment, laying the foundation for the development of high-tech industries.

　　"Large-capacity solid-state power lithium battery" is the exhibition project of "June 18th" this year. On June 21st, the tendering group signed an investment intention cooperation agreement with the project and the three-dimensional code project. At present, the project has basically completed the preliminary work and is preparing to start construction, while the three-dimensional code project is also progressing in an orderly manner and the investment will be completed in the near future. In addition, after the "6 18" exhibition, the bidding group also actively docked with Haixi Research Institute of Chinese Academy of Sciences and reached cooperation intentions on six-axis joint robots and other projects.

　　"While running’ 6 18′ well, relying on this innovative platform, we will seize the link of transformation and industrialization of scientific and technological achievements, promote the transformation and upgrading of’ 6 18′, and at the same time invest in a number of high-tech transformation projects, making it a new growth point and the focus of transformation and upgrading of the Group." Chen Wu said.

Source | A drug Buff

In December 2021, Pfizer COVID-19 took the medicine orally. Paxlovid Obtain FDA emergency use authorization.

In February 2022,Paxlovid It was approved by emergency conditions in National Medical Products Administration, China, and then it was written into the latest diagnosis and treatment plan.

Paxlovid It has been approved for listing in more than 50 countries around the world.

but Paxlovid　Its use in the real world is full of controversy.

"I thank the pharmaceutical companies for providing patients with effective COVID-19 therapy. But I am also frustrated that these companies seem to be in complete control of the situation, and I believe that Americans can get more benefits from pharmaceutical giants as long as our regulators dare to ask. Paxlovid was approved based on a study that seems to exaggerate the benefits that most Americans can get from this drug, rather than providing us with more information about it. " This is a primary care doctor at Weill Cornell Medical College in new york when talking about Covid-19’s therapeutic drugs. Paul Fenyves Some feelings.

Among the antiviral drugs in COVID-19, Pfizer’s Paxlovid Has become an obvious winner for two reasons:

Firstly, compared with monoclonal antibodies and Remdesivir, Paxlovid, as a pill, is easier to administer.

Secondly, Paxlovid seems to be very effective. A clinical trial shows that,Hospitalization or death of high-risk patients who received treatment decreased by 89%..

It seems to be very effective because there is a problem: FDA’s emergency use authorization (EUA) for Paxlovid is only based on the data of a single trial, and the trial only includes people who have never been vaccinated with COVID-19 vaccine before. At present, 76% of American adults have been vaccinated with COVID-19 vaccine, and it is estimated that 58% of Americans have been infected with Covid-19, so the experiment supporting Paxlovid EUA is not directly applicable to most Americans.

This means that doctors who treat patients with COVID-19 do not know to what extent (if any) Paxlovid can benefit patients who have been vaccinated. Doctors only have hope and speculation, and continue to prescribe Paxlovid to high-risk patients in COVID-19, but they are not sure whether they are really helping them.

Paxlovid Generic has been authorized in 95 countries.

History seems familiar.

Paxlovid’s current situation is reminiscent of previous antiviral drugs.oseltamivirIt was also controversial during the outbreak of swine flu.

Influenza kills an average of 40,000 Americans and hundreds of thousands of people around the world every year, so everyone is trying to develop antiviral drugs that can reduce its severity. Roche first introduced it in 1999.oseltamivir (oseltamivir), it is such a drug. Clinical studies reported by Roche show that existing evidence shows that Tamiflu reduces the risk of pneumonia, which is a common and important complication of influenza. For many years, doctors’ impression of using Tamiflu is that it reduces the risk of serious diseases.

Tamiflu (oseltamivir phosphate capsule) is indicated for the treatment of influenza A and B in adults and children over one year old. Patients should use it within 48 hours of the first symptom.

Tamiflu was included in the list of essential drugs by WHO. During the influenza outbreak in 2009, governments all over the world spent a lot of money to reserve a lot of Tamiflu to protect their citizens, because its manufacturer said, "Trust us, it works!" .

The Cochrane Collaboration made a meta-analysis of the clinical trial data of oseltamivir (Tamiflu) and zanamivir (Legonqing of GSK) and all published literature research results, and formed a comprehensive report, which was published in the British Medical Journal (BMJ) on April 10th, 2014.

The report pointed out that, oseltamivir can reduce the proportion of symptomatic influenza in prevention research.It can shorten the time needed for symptom relief in treatment research; However, there is no obvious effect in improving the hospitalization rate, and there is no strong evidence to support the reduction of influenza complications such as pneumonia, which has no obvious effect in reducing the spread of the virus. At the same time, it also questioned the practice of many countries in the world to reserve Tamiflu to prevent influenza pandemic.

In response to these reports, Roche issued a statement saying that it disagreed with the overall conclusion of Cochrane Collaboration Group. This report did not include all the data about Tamiflu, "only included 20 research data from 77 clinical trials they had mastered, and excluded the actual data obtained from observational trials".

However, in 2017, WHO adjusted Tamiflu from "core drug" in the list of essential drugs to "supplementary drug", and the applicable population was hospitalized critically ill patients who were diagnosed or suspected of influenza.

Although many doctors are skeptical about Tamiflu, they are like Paul Fenyves Similarly, they can’t ignore a drug that may be helpful to patients, especially the drug approved by the US Centers for Disease Control and Prevention. Therefore, doctors continue to prescribe Tamiflu to patients with high-risk influenza, hoping that the advantages outweigh the disadvantages.

Paxlovid’s data

Paxlovid’s situation is not exactly the same as Tamiflu’s, but there must be some "historical reappearance": doctors have to make clinical decisions on antiviral drugs for respiratory viruses without sufficient data.

There are two noteworthy facts about the people who participated in the Paxlovid trial. They were not vaccinated with Covid-19 vaccine and had never been infected with Covid-19 before.

First of all, even if the Paxlovid trial began in July 2021, only a few Americans were in the category of unvaccinated and uninfected with Covid-19, so the test results were never directly applicable to most Americans.

Secondly, Paxlovid is obviously more effective for people who have not been vaccinated with COVID-19 vaccine or have never been infected before, so the experiments supporting its use exaggerate the benefits that most people see from the drug.

Maybe you will say that Pfizer has started to test Paxlovid in high-risk population who have been vaccinated with COVID-19 vaccine, yes, but this trial is a mixture of vaccinated and unvaccinated patients, which may confuse the problem. More importantly, the test results will not be released until November 2022.

On April 29th, Pfizer released a phase II/III clinical (EPIC-PEP) study of Paxlovid for post-exposure prevention. The results show that,Paxlovid failed to reach the main end point, that is, effectively preventing the infection of family members who had contact with confirmed patients in COVID-19.. Therefore, Paxlovid has no preventive effect.

Who cares?

Pfizer’s first experiment exaggerated the efficacy of Paxlovid, which is not surprising, because as a pharmaceutical company, it has endless motivation to maximize its influence and promote sales.

But to everyone’s surprise, the US federal government will buy Paxlovid worth $5 billion, without Pfizer’s quick action to answer this basic question: "How does Paxlovid perform in high-risk groups who have been vaccinated with COVID-19 vaccine or previously infected?"

Paxlovid costs $530 (about 3,500 yuan) for a five-day course of treatment, but if there is no proper data, it is impossible to judge whether it is a good deal or a bad one. For example, if it is necessary to prescribe 10,000 courses of Paxlovid for people over 65 who have been vaccinated with COVID-19 vaccine to prevent one hospitalization, then a government may not place an order immediately; On the contrary, if 10 people can avoid a hospitalization by taking Paxlovid, they will be in a hurry to buy more.

However, if we don’t know the performance of Paxlovid in people who have been vaccinated with COVID-19 vaccine, it is impossible to make such calculations.

In addition, given the history of Tamiflu, the requirements for data transparency and independent review should be cautious.

Some people may say, even if we finally learn that Paxlovid’s benefits from people who have been vaccinated or infected before are greatly weakened, who cares?

But this problem is a symbol of a bigger problem: we lack the much-needed independent review of drug clinical trials.

Americans have seen scandals caused by poor supervision. When Covid-19 appeared, the pharmaceutical industry performed exceptionally well, providing safe and effective vaccines in record time. But before that, many Americans had "learned" not to trust Big Pharma, so many people (tragically) rejected this life-saving intervention.

Comparison of Action Mechanism between COVID-19 Vaccine and Oral Medicine

The discussion around "vaccine indecision" mainly focuses on false information, but what is missing is to admit that the pharmaceutical industry has wasted public trust for decades.

Instead of continuing to feel depressed about people who have not been vaccinated, we should reflect on ourselves and then start rebuilding the public’s trust step by step, which will be a long-term work.

　　The criminal suspect Lemou confessed to the crime of fraud by shaking audio and video. Photo courtesy of the police

　　Zhongxin. com, Changchun, September 18 (Sun Boyan, Chai Jiaquan) Changchun police reported on the 18 th that the police cracked a live webcast platform — — In the fraud case carried out by Shaking Audio and Video, one suspect was arrested, and many cases were solved in the first instance, involving more than 5 million yuan.

　　The case was jointly cracked by the Second Squadron of Criminal Police Brigade of Erdao Branch of Changchun Public Security Bureau and Qianjinbao Police Station. According to the police, in late July this year, the Qianjinbao police station in Erdao District of Changchun City received several reports from young women, claiming that they knew an anchor on the vibrato video, and after becoming a fan, they brushed gifts for him in the live broadcast room for a long time.

　　The anchor wooed through emotion and established a love relationship with many victims at the same time.

　　Lin Jiansen, political commissar of the Interpol Brigade of Erdao Branch of Changchun Municipal Public Security Bureau, said that the anchor tricked the victim into brushing gifts and filling tasks on the platform by setting up a media company to distribute the shares of the guild or because of difficulties in life. The victim believed it and brushed gifts for him in the live broadcast room with amounts ranging from several thousand yuan to several hundred thousand yuan.

　　Lin Jiansen said that when the victim had no money to brush the gift or could not complete the task, the criminal suspect cut him off from the WeChat friend to achieve the purpose of illegally possessing property.

　　Zhang Tong, director of Qianjinbao Police Station of Erdao Branch of Changchun Public Security Bureau, said that the main suspect in this case had 188,000 fans on the Tik Tok online platform and was praised by 1.38 million people. He was a typical public figure in online celebrity, with great social influence and far-reaching negative demonstration effect.

　　After the case occurred, Song Jindong, deputy head of Erdao District of Changchun City and director of the public security bureau, attached great importance to it, dispatched elite police forces from criminal police, Netan and police stations to set up a task force, and held several case judgment meetings to analyze the case, determine the investigation direction and guide the case investigation. The police of the task force collected and fixed a large amount of evidence from Beijing, Shanghai, Nanjing, Harbin and other places.

　　On the afternoon of September 17, the police of the task force decisively closed the net, arrested the suspect Le Mou in a residential area in Erdao District, Changchun City, and seized a large number of crime tools and posters such as laptops and mobile phones on the spot.

　　After the trial, the suspect Lemou confessed to the crime of fraud by shaking audio and video. At present, the person has been under criminal detention and the case is under further investigation.